Ophthalmic Focus Gemini Therapeutics is focused on genetically-defined dry AMD and related rare ocular diseases, creating opportunities for partnerships with ophthalmology CROs, imaging/biomarker vendors, and academic networks to co-develop targeted therapies and run disease-area specific trials.

Multimodal Pipeline Broad pipeline across monoclonal antibodies, recombinant proteins, and gene therapies suggests multiple collaboration angles and potential for licensing deals across modalities. Business development teams can position Gemini as a partner for modality-specific development, early KPIs, and manufacturing partnerships.

Strong BD Network Leadership includes seasoned ophthalmology and biotech executives with prior industry experience, and global academic partnerships indicate a ready-made network for deals, co-development, and strategic alliances.

Funding and Growth The company is well-funded and in clinical-stage development, signaling appetite for strategic partnerships and licensing to de-risk programs and accelerate progress.

Cambridge Advantage Based in Cambridge, MA, Gemini benefits from proximity to leading biopharma and academic ecosystems, enabling faster partner outreach, access to specialized talent, and potential for joint labs or clinical trial collaborations.